Patents by Inventor Ronald Christiaan Elgersma
Ronald Christiaan Elgersma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230144211Abstract: The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.Type: ApplicationFiled: December 22, 2022Publication date: May 11, 2023Inventors: Ronald Christiaan ELGERSMA, Tijl HUIJBREGTS, Dennis Christian Johannes WAALBOER, Johannes Albertus Frederikus JOOSTEN, Christina Adriana BEUCKENS-SCHORTINGHUIS
-
Patent number: 11419944Abstract: The present invention relates to linker-drug compounds (LDs) and antibody-drug conjugates (ADCs) comprising a non-linear self-immolative linker, which is cleavable or transformable under appropriate conditions and which reduces the hydrophobicity of the antibody-drug conjugate.Type: GrantFiled: October 11, 2017Date of Patent: August 23, 2022Assignee: Byondis B.V.Inventors: Ronald Christiaan Elgersma, Tijl Huijbregts, Rudy Gerardus Elisabeth Coumans
-
Publication number: 20220119392Abstract: The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.Type: ApplicationFiled: December 30, 2021Publication date: April 21, 2022Inventors: Ronald Christiaan ELGERSMA, Tijl HUIJBREGTS, Dennis Christian Johannes WAALBOER, Johannes Albertus Frederikus JOOSTEN, Christina Adriana BEUCKENS-SCHORTINGHUIS
-
Patent number: 11052155Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: GrantFiled: March 17, 2017Date of Patent: July 6, 2021Assignee: SYNTARGA BVInventors: Patrick Henry Beusker, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus De Groot
-
Publication number: 20200297859Abstract: The present invention relates to linker-drug compounds (LDs) and antibody-drug conjugates (ADCs) comprising a non-linear self-immolative linker, which is cleavable or transformable under appropriate conditions and which reduces the hydrophobicity of the antibody-drug conjugate.Type: ApplicationFiled: October 11, 2017Publication date: September 24, 2020Inventors: Ronald Christiaan ELGERSMA, Tijl HUIJBREGTS, Rudy Gerardus Elisabeth COUMANS
-
Publication number: 20180147289Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: ApplicationFiled: March 17, 2017Publication date: May 31, 2018Applicant: SYNTARGA BVInventors: Patrick Henry BEUSKER, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus De Groot
-
Publication number: 20180133316Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: ApplicationFiled: March 17, 2017Publication date: May 17, 2018Applicant: SYNTARGA BVInventors: Patrick Henry BEUSKER, Rudy Gerardus Elisabeth COUMANS, Ronald Christiaan ELGERSMA, Wiro Michael Petrus Bernardus MENGE, Johannes Albertus Frederikus JOOSTEN, Henri Johannes SPIJKER, Franciscus Marinus Hendrikus DE GROOT
-
Patent number: 9890159Abstract: The present invention relates to a process comprising converting a compound of formula (I) into a compound of formula (II) by reaction with an organolithium reagent, which compound can be further converted into duocarmycin analogs consisting of a DNA-alkylating and a DNA-binding part, and still further into corresponding antibody-drug conjugates.Type: GrantFiled: June 5, 2014Date of Patent: February 13, 2018Assignee: Synthon Biopharmaceuticals B.V.Inventors: Tijl Huijbregts, Ronald Christiaan Elgersma, Patrick Henry Beusker, Johannes Albertus Frederikus Joosten, Rudy Gerardus Elisabeth Coumans, Henri Johannes Spijker, Wiro Menge, Franciscus Marinus Hendrikus De Groot
-
Publication number: 20170333567Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: ApplicationFiled: March 17, 2017Publication date: November 23, 2017Applicant: SYNTARGA BVInventors: Patrick Henry BEUSKER, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus De Groot
-
Patent number: 9815784Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: GrantFiled: October 28, 2014Date of Patent: November 14, 2017Assignee: Syntarga B.V.Inventors: Patrick Henry Beusker, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus de Groot
-
Publication number: 20170274090Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: ApplicationFiled: March 17, 2017Publication date: September 28, 2017Applicant: SYNTARGA BVInventors: Patrick Henry BEUSKER, Rudy Gerardus Elisabeth COUMANS, Ronald Christiaan ELGERSMA, Wiro Michael Petrus Bernardus MENGE, Johannes Albertus Frederikus JOOSTEN, Henri Johannes SPIJKER, Franciscus Marinus Hendrikus DE GROOT
-
Publication number: 20170145006Abstract: The present invention relates to a process comprising converting a compound of formula (I) into a compound of formula (II) by reaction with an organolithium reagent, which compound can be further converted into duocarmycin analogues consisting of a DNA-alkylating and a DNA-binding part, and still further into corresponding antibody-drug conjugates.Type: ApplicationFiled: June 5, 2014Publication date: May 25, 2017Applicant: SYNTHON BIOPHARMACEUTICALS B.V.Inventors: Tijl HUIJBREGTS, Ronald Christiaan ELGERSMA, Patrick Henry BEUSKER, Johannes Albertus Frederikus JOOSTEN, Rudy Gerardus Elisabeth COUMANS, Henri Johannes SPIJKER, Wiro MENGE, Franciscus Marinus Hendrikus DE GROOT
-
Patent number: 9629924Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: GrantFiled: April 21, 2011Date of Patent: April 25, 2017Assignee: Syntarga BVInventors: Patrick Henry Beusker, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus De Groot
-
Publication number: 20160052880Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: ApplicationFiled: October 28, 2014Publication date: February 25, 2016Applicant: Syntarga BVInventors: Patrick Henry Beusker, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus de Groot
-
Patent number: 8889868Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: GrantFiled: November 3, 2009Date of Patent: November 18, 2014Assignee: Syntarga BVInventors: Patrick Henry Beusker, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michaƫl Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus de Groot
-
Publication number: 20130224227Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: ApplicationFiled: April 21, 2011Publication date: August 29, 2013Inventors: Patrick Henry Beusker, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus de Groot